Study guide
9.3 Respiratory Failure & Sleep-Disordered Breathing
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
9.3 Respiratory Failure & Sleep-Disordered Breathing
Key Takeaways Explain This Topic AI
Type 1 respiratory failure is defined by hypoxaemia (PaO2 <8.0 kPa) with a normal or low PaCO2 (<6.0 kPa), arising from ventilation-perfusion (V/Q) mismatch, true anatomical/physiological shunt, or alveolar-capillary diffusion barrier limitation.
Acute Respiratory Distress Syndrome (ARDS) is defined by the Berlin criteria: acute insult within 1 week, bilateral infiltrates not explained by heart failure, and PaO2/FiO2 ratio <=300 mmHg with PEEP >=5 cmH2O (mild: 201–300, moderate: 101–200, severe: <=100 mmHg).
Type 2 respiratory failure is characterized by hypoxaemia (PaO2 <8.0 kPa) with hypercapnia (PaCO2 >6.0 kPa), driven by alveolar hypoventilation due to central respiratory depression, neuromuscular pump failure, severe chest wall deformity, or terminal airflow obstruction.
Non-Invasive Ventilation (NIV / BiPAP) is indicated for acute hypercapnic respiratory failure in COPD exacerbations presenting with persistent respiratory acidosis (pH 7.25–7.35 and PaCO2 >6.0 kPa) despite optimal maximal medical therapy.
Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is confirmed by an Apnea-Hypopnea Index (AHI) >=15 events/hour (or >=5 with daytime somnolence); continuous positive airway pressure (CPAP) is first-line, and UK DVLA regulations mandate immediate driving cessation and notification when excessive daytime sleepiness occurs.
Last updated: September 2026
Respiratory failure occurs when the respiratory system fails to maintain adequate gas exchange, resulting in defective arterial oxygenation, defective carbon dioxide elimination, or both. In the MRCP(UK) Part 1 exam, candidates must master arterial blood gas (ABG) interpretation, distinguish physiological mechanisms of hypoxaemia, apply Berlin criteria for ARDS, know precise indications and settings for Non-Invasive Ventilation (NIV), and recall diagnostic criteria and legal driving requirements in sleep-disordered breathing.
1. Type 1 Respiratory Failure (Hypoxaemic)
Type 1 respiratory failure is defined by arterial hypoxaemia with a PaO2 < 8.0 kPa (60 mmHg) breathing room air, accompanied by a normal or low PaCO2 (<6.0 kPa / 45 mmHg) . Hyperventilation driven by hypoxaemic peripheral chemoreceptor stimulation typically causes hypocapnia and respiratory alkalosis.
Pathophysiological Mechanisms
Ventilation-Perfusion (V/Q) Mismatch: The most common physiological mechanism. Regions of lung receive inadequate ventilation relative to their perfusion (low V/Q ratio). Seen in pulmonary embolism, pneumonia, pulmonary oedema, asthma, and chronic obstructive pulmonary disease. Hypoxaemia caused by V/Q mismatch corrects readily with modest supplemental oxygen .
Right-to-Left Shunt (Intrapulmonary or Intracardiac): Deoxygenated blood bypasses ventilated alveolar spaces entirely and enters the arterial circulation unchanged (V/Q = 0). Examples include alveolar flooding (severe pneumonia, ARDS, acute pulmonary oedema), complete lobar atelectasis, pulmonary arteriovenous malformations (Osler-Weber-Rendu syndrome), or cyanotic congenital heart disease (Eisenmenger syndrome). True shunt hypoxaemia is refractory to supplemental oxygen therapy because non-ventilated lung units cannot oxygenate incoming blood regardless of alveolar FiO2.
Diffusion Impairment: Destruction or thickening of the alveolar-capillary membrane impairs oxygen transit time across the blood-gas barrier. Exemplified by idiopathic pulmonary fibrosis, fibrotic sarcoidosis, and systemic sclerosis-associated interstitial lung disease. At rest, transit time is sufficient, but hypoxaemia worsens significantly during exercise as pulmonary capillary transit time drops.
Alveolar Hypoventilation at High Altitude: Reduced inspired oxygen fraction ( P i O 2 P_iO_2 P i O 2 ) due to low barometric pressure, with normal alveolar-arterial (A-a) oxygen gradient.
Acute Respiratory Distress Syndrome (ARDS): The Berlin Definition
ARDS is a catastrophic form of acute non-cardiogenic diffuse alveolar injury characterized by increased alveolar-capillary membrane permeability, leakage of protein-rich fluid into the alveoli, surfactant loss, and extensive microvascular thrombosis.
The Berlin Definition of ARDS
Diagnostic Category Specific Criteria
Timing Acute onset within 1 week of a known clinical insult or new/worsening respiratory symptoms.
Chest Imaging Bilateral opacities on chest radiograph or CT scan not fully explained by pleural effusions, lobar/lung collapse, or pulmonary nodules.
Origin of Oedema Respiratory failure not fully explained by cardiac failure or hydrostatic fluid overload. Objective assessment (e.g., echocardiography) is required to exclude hydrostatic pulmonary oedema if no clear risk factor is present.
Oxygenation Impairment Assessed with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) >=5 cmH2O :; • Mild ARDS: 200 < PaO 2 / FiO 2 ≤ 300 mmHg 200 < \text{PaO}_2/\text{FiO}_2 \le 300\text{ mmHg} 200 < PaO 2 / FiO 2 ≤ 300 mmHg ; • Moderate ARDS: 100 < PaO 2 / FiO 2 ≤ 200 mmHg 100 < \text{PaO}_2/\text{FiO}_2 \le 200\text{ mmHg} 100 < PaO 2 / FiO 2 ≤ 200 mmHg ; • Severe ARDS: PaO 2 / FiO 2 ≤ 100 mmHg \text{PaO}_2/\text{FiO}_2 \le 100\text{ mmHg} PaO 2 / FiO 2 ≤ 100 mmHg
Oxygen Delivery Strategies in Type 1 Failure
High-Flow Nasal Oxygen (HFNO): Delivers heated, fully humidified gas mixtures at flow rates up to 60 L/min with accurate FiO2 (0.21–1.0). Physiological advantages include washout of anatomical dead space (nasopharyngeal reservoir), reduction in work of breathing, and delivery of a modest positive airway pressure (~2–5 cmH2O).
Continuous Positive Airway Pressure (CPAP): Delivers constant positive pressure throughout inspiration and expiration. It recruits collapsed alveoli, increases Functional Residual Capacity (FRC), decreases intrapulmonary shunt, and drives fluid out of alveolar spaces into the interstitial lymphatic bed. First-line non-invasive therapy for acute cardiogenic pulmonary oedema .
2. Type 2 Respiratory Failure (Hypercapnic)
Type 2 respiratory failure is characterized by hypoxaemia (PaO2 < 8.0 kPa) accompanied by hypercapnia (PaCO2 > 6.0 kPa / 45 mmHg) , representing failure of alveolar ventilation ("pump failure").
Pathophysiological Categories & Etiologies
Depressed Central Respiratory Drive:
- Drug-induced respiratory depression (opioids, benzodiazepines, barbiturates, general anaesthetics)
- Brainstem lesions (infarction, hemorrhage, trauma, encephalitis)
- Central sleep apnoea and severe obesity hypoventilation syndrome
Neuromuscular Respiratory Muscle Weakness (Pump Failure):
- Motor neurone disease (amyotrophic lateral sclerosis)
- Guillain-Barré syndrome
- Myasthenia gravis crisis (myasthenic crisis)
- Cervical spinal cord injury (above C3–C5 involving phrenic innervation)
- Severe electrolyte depletion (profound hypophosphataemia, hypokalaemia, hypomagnesaemia)
Clinical Clue: Paradoxical abdominal motion (inward movement of abdomen on inspiration), marked orthopnoea, and a drop in Forced Vital Capacity (FVC) >20% from sitting to supine position.
Thoracic Cage & Chest Wall Deformities:
Severe kyphoscoliosis, ankylosing spondylitis with thoracic rigidity, thoracoplasty, flail chest, massive morbid obesity (chest wall loading).
Increased Mechanical Workload & Severe Airflow Limitation:
- Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
- Life-threatening acute severe asthma (exhaustion)
- End-stage cystic fibrosis and severe non-CF bronchiectasis
Obesity Hypoventilation Syndrome (OHS / Pickwickian Syndrome):
Triad of BMI >=30 kg/m² , daytime hypercapnia ( PaCO2 >6.0 kPa ), and sleep-disordered breathing, in the absence of alternative causes of hypoventilation.
3. Non-Invasive Ventilation (NIV / BiPAP)
Non-Invasive Ventilation using Bilevel Positive Airway Pressure (BiPAP) delivers two distinct levels of positive airway pressure: Inspiratory Positive Airway Pressure (IPAP) , which augments tidal volume to blow off CO2 and reduce the work of breathing, and Expiratory Positive Airway Pressure (EPAP) , which splints open airways, maintains functional residual capacity, and enhances alveolar oxygenation.
Primary Indication in COPD
According to BTS and NICE guidelines, NIV is indicated in patients with an acute exacerbation of COPD presenting with acute hypercapnic respiratory failure and uncompensated respiratory acidosis : Arterial pH 7.25 to 7.35 and PaCO 2 > 6.0 kPa \text{Arterial pH } 7.25 \text{ to } 7.35 \quad \text{and} \quad \text{PaCO}_2 > 6.0\text{ kPa} Arterial pH 7.25 to 7.35 and PaCO 2 > 6.0 kPa
persisting despite optimal initial medical therapy for at least 60 minutes (controlled oxygen via 24–28% Venturi mask to maintain SaO2 88–92%, nebulised salbutamol and ipratropium, oral prednisolone 30 mg or IV hydrocortisone, and empirical antibiotics if sputum purulence is present).
The pH < 7.25 Threshold: If the arterial pH is <7.25, NIV should still be initiated without delay, but the patient must be managed in a high-dependency (HDU) or intensive care (ICU) environment with immediate preparation for invasive endotracheal intubation and mechanical ventilation should NIV fail.
- Contraindications to NIV
- Facial trauma, burns, extensive facial deformity, or recent facial/upper gastrointestinal surgery
- Fixed upper airway obstruction
Severe encephalopathy, coma, or inability to protect the airway (except when NIV is explicitly designated as the ceiling of care in COPD)
- Active vomiting or severe gastrointestinal bleeding (high risk of fatal pulmonary aspiration)
- Undrained tension pneumothorax or massive hemothorax
- Severe hemodynamic instability (uncontrolled cardiogenic or septic shock)
- Initial Settings & Monitoring Protocol
Starting Pressures: IPAP 10–12 cmH2O ; EPAP 4–5 cmH2O .
Titration: Rapidly titrate IPAP upwards in increments of 2–3 cmH2O every 15–30 minutes up to 16–20 cmH2O to achieve a target tidal volume of 6–8 mL/kg predicted body weight and clinical resolution of tachypnoea.
Repeat Arterial Blood Gas: Mandatory at 1 hour after initiating NIV, and again at 4 hours . Successful response is demonstrated by a rising pH, falling PaCO2, reduction in respiratory rate, and clinical stabilization.
4. Sleep-Disordered Breathing & OSAHS
Sleep-disordered breathing encompasses obstructive sleep apnoea-hypopnoea syndrome (OSAHS), central sleep apnoea (CSA), and obesity hypoventilation syndrome.
Obstructive Sleep Apnoea-Hypopnoea Syndrome (OSAHS)
OSAHS is characterized by repetitive collapse and occlusion of the upper pharyngeal airway during sleep, resulting in transient cessation of airflow ( apnoea ; airflow reduction >=90% for >=10 seconds) or partial reduction ( hypopnoea ; airflow reduction >=30% for >=10 seconds accompanied by >=3% oxygen desaturation or electroencephalographic arousal).
- Risk Factors & Etiology
- Male sex (2–3 times higher prevalence)
- Obesity (BMI >30 kg/m²; fat deposition in parapharyngeal soft tissues narrows the pharyngeal lumen)
- Increased collar/neck circumference: >43 cm (17 inches) in men; >40 cm (16 inches) in women
Craniofacial abnormalities: Retrognathia, micrognathia, maxillary hypoplasia, macroglossia (e.g., Down syndrome, acromegaly), tonsillar hypertrophy
- Systemic disorders: Hypothyroidism, acromegaly, polycystic ovary syndrome (PCOS)
- Exogenous agents: Evening alcohol consumption and sedative medications (relax upper airway dilator muscles)
- Clinical Features & Epworth Sleepiness Scale (ESS)
Nocturnal Symptoms: Habitual loud snoring, witnessed apnoeic pauses, choking/gasping arousals, restless unrefreshing sleep, nocturia.
Daytime Symptoms: Excessive daytime somnolence, morning frontal headaches, cognitive impairment, poor concentration, irritability, personality changes, impotence/loss of libido.
Epworth Sleepiness Scale (ESS): Validated 8-item self-administered questionnaire evaluating the likelihood of dozing in routine daytime situations (scored 0 to 24). A score >10 indicates abnormal, excessive daytime sleepiness.
Diagnostic Polysomnography & AHI Severity
Definitive diagnosis requires overnight respiratory polygraphy or full in-laboratory polysomnography (recording EEG, EOG, EMG, airflow, thoracic-abdominal effort, and pulse oximetry):
Apnoea-Hypopnoea Index (AHI): The average number of apnoeas and hypopnoeas recorded per hour of sleep:
- Normal: AHI < 5 events/hour
- Mild OSAHS: AHI 5 to 14 events/hour
- Moderate OSAHS: AHI 15 to 29 events/hour
- Severe OSAHS: AHI >= 30 events/hour
- Treatment Modalities
Continuous Positive Airway Pressure (CPAP): Gold-standard, first-line treatment for moderate to severe OSAHS (AHI >=15), and for mild OSAHS with refractory daytime symptoms. CPAP acts as a pneumatic splint, preventing pharyngeal collapse.
Mandibular Advancement Splints (MAS): Customized intraoral dental appliances that advance the mandible and tongue base. Indicated in mild-to-moderate OSAHS or patients unable to tolerate CPAP.
Lifestyle Modifications: Supervised weight loss (bariatric surgery if BMI >=35–40 kg/m²), complete cessation of evening alcohol and sedatives, and positional therapy (sleep position trainers to avoid supine sleep).
UK DVLA Driving Regulations (Critical Exam Knowledge)
Under UK Driver and Vehicle Licensing Agency (DVLA) regulations:
Any patient diagnosed with OSAHS who suffers from excessive daytime sleepiness that impairs or is likely to impair safe driving must immediately cease driving and must notify the DVLA .
Failure to notify the DVLA is a criminal offence.
Driving may resume once satisfactory symptom control has been established (typically verified by objective CPAP compliance data downloads showing usage >4 hours per night on >=70% of nights) and formal confirmation is received from the DVLA.
Professional/vocational drivers (Group 2 license holders: lorries and buses) are subject to stricter compliance standards and mandatory annual specialist clinical reviews.